News

Antibody candidate developed with new technology from Jan Terje Andersen's group is now in clinical trial to test the safety in healthy participants

"Engineering immune-evasive allogeneic cellular immunotherapies"

PRIMA Synergy grant project leader Postdoc Lamberto Torralba-Raga has been awarded 100 000 USD for his cell engineering project.

Get to know Pegah Nammian in Lund-Johansen lab! Pegah started her work in PRIMA in March 2024

YSWG - the Young Scientist Working Group - is an organization of engaged and motivated young scientists from PRIMA that works to promote career development and networking between the students and young scientists in PRIMA.

Andersen’s research group has recently published their new REW technology in Nature Communication.

Get to know Alenka D. Behsen in the Malmberg Lab! Behsen was recruited to PRIMA in February 2024

Professor Johanna Olweus, codirector and PI in PRIMA, has been extensively interviewed for a feature article in "The Scientist" magazine, entitled "Next-generation CAR and TCR Cancer Therapies"

PRIMA PI Jan Terje Andersen is elected as a member of the Norwegian Academy of Science and Letters (DNVA) - a non-governmental, nationwide body founded in 1857 that embraces all fields of science with the purpose to support the advancement of science and scholarship in Norway.

Cancer Grand Challenges team MATCHMAKERS  with Johanna Olweus as one of the principal investigators, was one of five global teams selected to receive 25$ each over 5 years.

Before he died, Victor Dyreng asked his mom to collect money to support cell therapy research. The story about Victor and his mom's commitment to support research in the Olweus research group was published in the national newspaper, VG, January

Get to know Colin LaMont in Myklebust Lab! Colin was one the first new recruitments to PRIMA 

Article in Nordic Life Science news by PRIMA PI Prof Jan Terje Andersen and Hanne Mette Dyrlie Kristensen, CEO Life Science Cluster and mentor in the Mentoring Programme at PRIMA. 

PRIMA PI Johanna Olweus and Dr. Morten Milek Nielsen was January 3 interviewed in the Cell Therapy Podcast by KITE Gilead. In this episode, they talk about the use of T cell receptors (TCR’s) as immunotherapy against cancer.

Six months have elapsed since the Precision Immunotherapy Alliance (PRIMA) commenced its operations and Director Kalle Malmberg reflects on the past months events.

Feature story in Aftenposten Dec 7, 2023, by PRIMA Co-Director Johanna Olweus, Kjetil Taskén and John Arne Røttingen on the use of mRNA in cancer treatment and in the prevention of infections.

PRIMA was so lucky to host a group of highly motivated and interested students from Sandvika VGS who used a day in the center to learn more about precision immunotherapy.

A recent publication from the Olweus group entitled "A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo" is profiled in ACIR. 

Mage Biologics Inc (Mage Bio) is a new U.S.-based biotech company developing a tailored antibody that can be administered orally for treatment of chronic diseases in the gut.

The Laboratory of Adaptive Immunity and Homeostasis, headed by PRIMA PI Jan Terje Andersen, has signed a framework agreement with Roche Diagnostics GmbH and entered a research collaboration with the aim to gain a deeper understanding on how FcRn-targeted molecules are handled in both in vitro and in vivo systems.

The whole PRIMA family was gathered for the first scientific meeting in the centre from August 30-31 with the aim of getting to know each other’s expertise and research.

Researchers have identified a novel immunotherapy for acute myeloid leukemia (AML). Immune cells are programmed to recognize a mutation found in leukemia patients. The results provide hope for new and effective treatment for the most common form of leukemia in adults.

Congratulations to our brilliant postdoc Zsofia Fôldvari on her paper in the Nature Partner Journal (NPJ) Vaccines, outlining a much-needed strategy to select safe T-cell receptors!

Professor Johanna Olweus has been selected for the final of the Cancer Grand Challenges as part of a global research team. If successful, the team hopes to contribute in giving cancer patients new therapies.

Wednesday 21 June was the official opening of the new Centre of Excellence (CoE), PRIMA. The Centre's aim is to develop new and more effective immunotherapy that will improve cancer treatment and cure more patients.